Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 31, Issue 3, 2009, Pages 183-226

  Tomillero, A ^a   Moral, M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMBRISENTAN; BERAPROST; BOSENTAN; CCX 282; CERTOLIZUMAB PEGOL; CLEVUDINE; CNTO 328; CROFELEMER; DAPTOMYCIN; DEFERASIROX; DEXAMETHASONE; FARGLITAZAR; FLUINDOSTATIN; FX 06; ILOPROST; IMATINIB; INCB 18424; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; JNJ 26854165; LANDIOLOL; MEVINOLIN; MIGLUSTAT; MK 0493; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NESIRITIDE; OLMESARTAN; OMEPRAZOLE; PARATHYROID HORMONE[1-34]; PHA 848125; PIOGLITAZONE; PRAVASTATIN; PRUCALOPRIDE; REVAPRAZAN; RWJ 676070; SILDENAFIL; SIMVASTATIN; SITAGLIPTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UP 780;

AMYLOIDOSIS; ANEMIA; ANGINA PECTORIS; APLASTIC ANEMIA; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BACTEREMIA; BURN; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; CROHN DISEASE; DIABETES MELLITUS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; EISENMENGER COMPLEX; ENTERITIS; EOSINOPHILIA; FASCIITIS; FRACTURE; GAUCHER DISEASE; HEART FAILURE; HEPATITIS B; HEPATITIS C; HIDRADENITIS; HUMAN; HYPOPHOSPHATASIA; ILEUS; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER FIBROSIS; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PAIN; POSTMENOPAUSE OSTEOPOROSIS; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; SKIN INFECTION; STOMACH ULCER; THALASSEMIA; TREATMENT OUTCOME; WOUND INFECTION; ARTICLE;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 70249136226     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (269)

1. Bittencourt, H., Macedo, A.V., Fischer, G. et al. Allogeneic bone marrow transplantation with cyclophosphamide and low dose alemtuzumab for severe aplastic anemia. Haematologica 2008, 93(Suppl. 1): Abst 0824.
2. Rondoni, M., Baccarani, M., Paolini, S. et al. Imatinib mesylate induces complete and durable responses in all patients with the FIP1L1- PDGFRalpha positive hypereosinophilic syndrome: Clinical and molecular follow-up of the Italian multicenter prospective study. Haematologica 2008, 93(Suppl. 1): Abst 0742.
3. Desmond, R., Conway, H., McMahon, C., Geoghegan, R., Elwan, H. Iron overload and the role of oral chelators in the management of a paediatric population on chronic transfusion programmes: Efficacy and tolerability. Haematologica 2008, 93(Suppl. 1): Abst 0854.
4. Rossebø, A.B., Pedersen, T.R., Boman, K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. New Engl J Med 2008, 359(13): 1343.
5. Varenhorst, C., James, S., Erlinge, D. et al. Assessment of the platelet inhibitory effects of clopidogrel and prasugrel by the Verify Now P2Y12 point-of-care device in comparison with LTA and VASP-phosphorylation in aspirin treated CAD patients. Eur Heart J 2008, 29(Suppl.): Abst P2597.
6. Brudi, P., Reckless, J.P.D., Henry, P. et al. Does the efficacy of ezetimibe/simvastatin 10/40 mg differ from dose-doubling of different potency statins in patients with a recent coronary event? J Clin Lipidol 2008, 2(Suppl. 5): Abst 63.
7. Isobe, S., Sato, K., Sugiura, K. et al. Feasibility and safety of intravenous administration of landiolol hydrochloride in multislice computed tomography coronary angiography. Eur Heart J 2008, 29(Suppl.): Abst P1519.
8. Duplyakov, D., Skuratova, M., Kuzmin, V. et al. Low-dose rosuvastatin vs. high-dose fluvastatin in patients with CAD after interventional care (CABG/PCI). Eur Heart J 2008, 29(Suppl.): Abst P1407.
9. Hirohata, A., Yamaji, H., Murakami, M. et al. Impact of olmesartan on progression of coronary atherosclerosis; a serial volumetric IVUS analysis from the OLIVUS trial. Circulation 2008, 118(18, Suppl.): Abst 2511.
10. Michaels, A.D., Karabsheh, S.M. Nesiritide acutely prolongs electromechanical activation time, a non-invasive acoustic cardiographic marker of contractility, in heart failure patients. J Cardiac Fail 2008, 14(6, Suppl.): Abst 029.
11. Atar, D., Petzelbauer, P., Schwitter, J. et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009, 53(8): 720.
12. Galie, N., Richards, D., Hutchinson, T., Dufton, C. Ambrisentan therapy for patients with PAH associated with connective tissue disease (PAH-CTD): One year follow-up. Eur Respir J 2008, 32(Suppl. 52): Abst E1418.
13. Tan, L., Tan, S. Sitagliptin decreases C-reactive protein, monocyte chemotactic protein-1, myeloperoxidase activity and interleukin-6 in diabetics with atherosclerosis. J Clin Lipidol 2008, 2(Suppl. 5): Abst 293.
14. Tan, L.G., Tan, S.A., Berk, L.S. Rosuvastatin+pioglitazone decrease interferon- gamma, TNF-alpha, IL-6, MCP-1, myeloperoxidase, CRP, and increase IL-4 in diabetics with atherosclerosis. J Clin Lipidol 2008, 2(Suppl. 5): Abst 33.
15. Hirono, K., Ibuki, K., Saito, K. et al. Bosentan induces clinical and hemodynamic improvement in candidates for right heart bypass surgery. Circulation 2008, 118(18, Suppl.): Abst 2610.
16. Aboulhosn, J., Houser, L., Child, J.S., Levine, M.S., Miner, P. Efficacy of bosentan in adults with complex anatomy and Eisenmenger syndrome. Circulation 2008, 118(18, Suppl.): Abst 2613.
17. Iversen, K.K., Soendergaard, L., Vejlstrup, N.G., Jensen, A.S. Combination therapy with bosentan and sildenafil to patients with Eisenmenger's syndrome. Eur Heart J 2008, 29(Suppl.): Abst P4750.
18. Giraldo, P., Latre, P., Acedo, A. et al. Long term efficacy and safety of miglustat therapy in type 1 Gaucher disease: ZAGAL study. Haematologica 2008, 93(Suppl. 1): Abst 1071.
19. Camacho, P.M., Kadanoff, R., Mazhari, A.M. Adult hypophosphatasia treatment with teriparatide. J Bone Miner Res 2008, 23(Suppl. 1): Abst SA468.
20. Kummerle-Deschner, J., Blank, N., Roesler, J. et al. ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS). Pediatr Rheumatol 2008, 6(Suppl. 1): Abst O26.
21. Reyal, Y., Chowdhury, O., Shah, F., Prescott, E., Davis, B., Kirk, P. Improvement in cardiac T2* with deferasirox in transfused patients with cardiac iron overload. Haematologica 2008, 93(Suppl. 1): Abst 0846.
22. Wakabayashi, T., Oshima, Y., Sakaguchi, H. et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008, 115(9): 1571.
23. Hetzel, D.J., Gibson, P.R., Radford-Smith, G., Macrae, F., Bekker, P., Schall, T.J. CCX282-B, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of protect-1 clinical trial in Crohn's disease. J Gastroenterol Hepatol 2008, 23(Suppl. 4): Abst.
24. Condino, G., Calabrese, E., Petruzziello, C. et al. Treatment with antitumor necrosis factor alpha antibodies and sub-obstructive symptoms in Crohn's disease: Prospective longitudinal study. Gut 2008, 57(Suppl. 2): Abst P0725.
25. Schreiber, S., Feagan, B., Sandborn, W., Lichtenstein, G. The long-term efficacy and tolerability of certolizumab pegol therapy for Crohn's disease. Gut 2008, 57(Suppl. 2): Abst OP310.
26. Trinder, M., Lawrance, I.C. Initial experience of adalimumab efficacy in the management of IBD in the clinical setting. J Gastroenterol Hepatol 2008, 23(Suppl. 4): Abst.
27. Sharma, A.D., Dinakaran, N., Baliga, V.P., Bolmall, C., Rajadhyaksha, G. A double-blind, randomized, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of crofelemer in the treatment of adult patients with acute infectious diarrhea. Gut 2008, 57(Suppl. 2): Abst OP340.
28. Kamm, M.A., Emmanuel, A.V., Kerstens, R., Vandeplassche, L. Doubleblind, placebo-controlled, cross-over, multiple (N=1) trial to evaluate the effects of prucalopride in patients with chronic intestinal pseudo-obstruction (CIP). Gut 2008, 57(Suppl. 2): Abst P0900.
29. Karmiris, K., Noman, M., Rutgeerts, P., Van Assche, G., Vermeire, S. Efficacy of adalimumab on extra-intestinal manifestations in patients with inflammatory bowel disease. Gut 2008, 57(Suppl. 2): Abst P0748.
30. Chang, R. Phase III clinical trial of revaprazan (Revanex) for gastric ulcer. J Gastroenterol Hepatol 2008, 23(Suppl. 5):Abst.
31. Shiffman, M.L., Sterling, R.K., Hofmann, C., Sanyal, A.J., Leung, D.A., Tisnado, J., Smith, P.G. Low does peginterferon alfa-2a maintenance therapy reduces portal pressure in patients with advanced fibrosis and cirrhosis. Hepatology 2008, 48(4, Suppl.): Abst 1654.
32. Ljunggren, Ö., Fahrleitner-Pammer, A., Kutahov, A. et al. Back pain is reduced in postmenopausal women with severe osteoporosis treated with rhPTH(1-34) (teriparatide) regardless of incident fractures: 18 month results from the European Forsteo Observational Study (EFOS). J Bone Miner Res 2008, 23(Suppl. 1): Abst SU413.
33. McHutchison, J.G., Gardner, S.D., Makhlouf, H.R. et al. Double-blind, randomized, placebo-controlled, multi-center, phase II dose-ranging study to assess the anti-fibrotic activity of farglitazar in chronic hepatitis C infection. Hepatology 2008, 48(4, Suppl.): Abst 1859.
34. Kang, M.-J., Song, H.J., Jung, J.M. et al. One-year follow-up of biochemical and virological response of clevudine therapy in patients with chronic hepatitis B-associated liver cirrhosis. Hepatology 2008, 48(4, Suppl.): Abst 968.
35. Canovas, A., Barreiro, G., Alonso, J.J. Treatment of light chain (AL) amyloidosis with bortezomib and dexamethasone. Haematologica 2008, 93(Suppl. 1): Abst 1108.
36. Arns, W., Sommerer, C., Pietruck, F. et al. Multicenter, open-label, prospective, randomized, parallel group study investigating an everolimusbased CNI-free regimen in comparison to a cyclosporine-based standard therapy in de novo renal transplant patients (ZEUS study). Nieren- Hochdruckkr 2008, 37(9): Abst FV 31.
37. Friedman, B., Shaver, J.R., Mullins, R.F. et al. Daptomycin use for a variety of wound types in a burn and wound care facility - update on current use. Intensive Care Med 2008, 34(Suppl. 1): Abst 0098.
38. Hadziyannis, S.J., Dimou, E., Rapti, I. Adefovir dipivoxil add-on treatment to lamivudine resistant HBeAg-negative chronic hepatitis B patients: 5- year follow-up data of an ongoing prospective study. Hepatology 2008, 48(4, Suppl.): Abst 924.
39. Kar, P., Kumar, S.P. A comparative evaluation of adefovir and lamivudine in patients of chronic hepatitis B, correlation with HBV viral kinetics, hepatic necro-inflammation and fibrosis. J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
40. Kim, S.E., Chung, Y.-H., Kim, J.A. et al. Durability of adefovir dipivoxil induced HBeAg loss following long-term additional therapy in patients with YMDD mutants of hepatitis B virus. Hepatology 2008, 48(4, Suppl.): Abst 890.
41. Park, N.H., Chung, Y.-H., Kim, J.A. et al. Add-on clevudine therapy in patients with adefovir dipivoxil resistant chronic hepatitis B: In comparison with add-on lamivudine therapy. Hepatology 2008, 48(4, Suppl.): Abst 961.
42. Sul, H.R., Kim, H.J., Lee, H.W. et al. The comparison of 24 weeks treatment efficacy between entecavir and clevudine in treatment-naive patients with chronic hepatitis B. Hepatology 2008, 48(4, Suppl.): Abst 912.
43. Omata, M., Takaguchi, K., Fujioka, S. et al. Long-tern efficacy, safety and resistance analyses of entecavir (ETV) treatment in Japanese nucleosidenaive patients with chronic hepatitis B (CHB). J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
44. Rao, P.N., Reddy, D.N., Gupta, R., Sharma, S. Efficacy of entecavir in hepatitis B virus (HBV) related chronic liver disease patients in a tertiary care from South India - an open-label study data. J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
45. Kim, H.J., Lee, J.H., Lee, J.S. Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks. J Gastroenterol Hepatol 2008, 23(Suppl. 4): Abst.
46. Schiff, E., Simsek, H., Lee, W.M. et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008, 103(11): 2776.
47. Behal, R., Piramanayagam, P., Choudhuri, G., Srivastava, P., Upadhyay, P. Efficacy of entecavir in lamivudine resistant hepatitis B patients. J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
48. Chang, T.T., Kreter, B., Desmond, P. et al. Long-term follow-up of entecavir treated protocol-defined non-responders in rollover study ETV-901. J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
49. Everhard, F., Deniz, H.B. Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (TDF), lamivudine (LAM), adefovir dipivoxil (ADV) and entecavir (ETV) in HBeAg negative (-) patients with chronic hepatitis B (CHB) in the USA. Hepatology 2008, 48(4, Suppl.): Abst 976.
50. Liaw, Y.F., Gane, E., Leung, N. et al. Papatheodoridis, G., Chen, Y., Brown, N.A., Albanis, E., Galil, K., Naoumov, N.V.; 2-Year GLOBE trial results: Telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136(2): 486.
51. Snow-Lampart, A., Chappell, B.J., Curtis, M., Borroto-Esoda, K., Heathcote, E.J., Marcellin, P., Zhu, Y. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD. Hepatology 2008, 48(4, Suppl.): Abst 977.
52. Absalon, J., Thal, G., McGrath, D., Yang, R., Mancini, M.D., Thiry, A. Atazanavir is safe and efficacious in HBV and HCV co-infected patients: Results of AI424138 (CASTLE). J Int AIDS Soc 2008, 11(Suppl. 1): Abst P136.
53. Saigal, S., Saraf, N., Kakodkar, R. et al. Management of HCV recurrence in living donor liver transplant recipients with pegylated interferon and ribavirin. J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
54. Kontorinis, N., Nazareth, S., McInerney, M., Cheng, W. Outcome of HCV therapy with interferon and ribavirin in indigenous Australian Aboriginals. J Gastroenterol Hepatol 2008, 23(Suppl. 4): Abst.
55. Lee, J.H., Yoo, B.C., Lee, J.S., Kim, H.J. HCV RNA at 12 weeks after treatment can predict sustained virologic response in chronic hepatitis C patients treated with pegylated interferon and ribavirin. J Gastroenterol Hepatol 2008, 23(Suppl. 4): Abst.
56. Balart, L.A., Rodriguez-Torres, M., Hamzeh, F.M. Histologic response to peginterferon alfa-2a plus ribavirin in treatment-naïve Latino and non- Latino white patients infected with HCV genotype 1: The LATINO study. Hepatology 2008, 48(4, Suppl.): Abst 1862.
57. Kaiser, S., Werner, C.R., Hass, H.G., Lutze, B. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2a (40KD) plus ribavirin for 72 weeks. Hepatology 2008, 48(4, Suppl.): Abst 1860.
58. Rumi, M., Aghemo, A., Prati, G.M. et al. Randomized study comparing peginterferon-alfa2a plus ribavirin and peginterferon-alfa2b plus ribavirin in naïve patients with chronic hepatitis C: Final results of the Milan Safety Tolerability (MIST) study. Hepatology 2008, 48(4, Suppl.): Abst 212.
59. Takaguchi, K., Nagano, T., Wato, M. et al. Peginterferon alfa-2a monotherapy could be a treatment option for chronic hepatitis C in patients infected with HCV genotype 2. Hepatology 2008, 48(4, Suppl.): Abst 512.
60. Ahmad, W., Hughes, D., Dunnam, M., Khan, Q., Fazili, J. The impact of filgrastim and epoetin use on sustained viral response (SVR) rates in hepatitis C patients treated with PEG-interferon and ribavirin. Am J Gastroenterol 2008, 103(Suppl. 1): Abst 369.
61. Kim, C., Byun, K.S., Kim, J.H. et al. The clinical significance of interferon inducible protein-10 in chronic hepatitis C patients with genotype I undergoing pegylated interferon and ribavirin therapy. J Gastroenterol Hepatol 2008, 23(Suppl. 5): Abst.
62. Forns, X., Marcellin, P., Goeser, T. et al. Phase 2 study of telaprevir administered q8h or q12h with pegintrferon-alfa-2a or -alfa-2b and ribavirin in treatment-naïve subjects with genotype 1 hepatitis C: Week 4 interim results. Hepatology 2008, 48(4, Suppl.): Abst 1854.
63. Shiffman, M.L., Berg, T., Poordad, F.F. et al. A study of telaprevir combined with peginterferon-alfa-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa-2a and ribavirin treatment: Interim analysis. Hepatology 2008, 48(4, Suppl.): Abst 1852.
64. Rodriguez-Torres, M., Rockstroh, J., Torriani, F., Carosi, G., Dieterich, D.T., Depamphilis, J. Prediction of SVR in HCV genotype 1 patients co-infected with HIV based on virological responses at week 4 and 12 of treatment with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS): Retrospective analysis of APRICOT. Hepatology 2008, 48(4, Suppl.): Abst 1855.
65. Janke, M., Luechters, G., Vogel, M. et al. Rapid virological response is the best predictor for achieving SVR under peg-IFN/ribavirin hepatitis C therapy in HIV/HCV co-infected patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P266.
66. Adler, M., Matloff, J.L., Boxer, A.S., Dieterich, D.T., Vachon, M.-L., Carriero, D.C., Han, H. In chronic hepatitis C (HCV), pretreatment with thiazolidinediones (TZDS) or metformin decreases insulin resistance (IR) and HCV viral load and increases early virologic response (EVR). Hepatology 2008, 48(4, Suppl.): Abst 1891.
67. Giulio, G., Farina, G., Piano, S., Storti, S., Nicci, C., Marcellino, A., Grafone, T. Prophylaxis with acyclovir in bortezomib-dexamethasone based therapy for multiple myeloma reduces the incidence of HZV, but not CMV infection. Haematologica 2008, 93(Suppl. 1): Abst 1297.
68. Waters, L.J., Randell, P., Jackson, A.G.A., Moyle, G.J., Mandalia, S., Gazzard, B.G., Taylor, J. A cross-sectional comparison of renal function in patients on stable abacavir (ABC) or tenofovir (TDF) containing therapy. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P129.
69. Wolf, E., Trein, A., Stellbrink, H.J., Baumgarten, A., Jaeger, H., Schmidt, W. Similar virological response rates for ART-naive subjects starting KVX + LPV/r or TVD + LPV/r: Data from the prospective observational STAR cohort. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P7.
70. Cahn, P., Altclas, J., Martins, M., Cooper, D.A., Cassetti, I., Cox, S., Losso, M. Forty eight-week data from study AVX-201 - a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. J Int AIDS Soc 2008, 11(Suppl. 1): Abst O414.
71. Casana, M., Barassi, A., Cicconi, P. et al. Predictors of severe hyperbilirubinemia in HIV-infected patients treated with atazanavir (ATV). J Int AIDS Soc 2008, 11(Suppl. 1): Abst P235.
72. Giola, M., Cusato, M., Villani, P. et al. Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P234.
73. Uy, J., Yang, R., Thiry, A., McGrath, D., Farajallah, A., Maa, J.F., Absalon, J. Efficacy and safety by baseline HIV-RNA and CD4 count in treatmentnaive patients treated with atazanavir/r and lopinavir/r in the CASTLE study. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P8.
74. Labarga, P., Barreiro, P., Martin-Carbonero, L. et al. Kidney tubular abnormalities in HIV patients treated with tenofovir with normal glomerular function - results of a prospective study on 284 patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P128.
75. Pozniak, A., Arastéh, K., Molina, J.M., Spinosa-Guzman, S., De Meyer, S., Van De Casteele,T., Grinsztejn, B. POWER 3 analysis: One hundred and forty four-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P24.
76. Fätkenheuer, G., Clotet, B., Pialoux, G. et al. Safety analysis of darunavir/r (DRV/r): Combined data from randomised phase II and phase III studies. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P157.
77. Katlama, C., Bellos, N., Grinsztejn, B. et al. POWER 1 and 2: Combined final one hundred and forty four-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P21.
78. Bánhegyi, D., Katlama, C., Da Cunha, C. et al. Phase III TITAN week 96 final analysis: Efficacy/safety of darunavir/r (DRV/r) vs lopinavir/r (LPV/r) in LPV-naive, treatment-experienced patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P22.
79. Peeters, M., Vingerhoets, J., Tambuyzer, L., Picchio, G., Hill, A.M., De Meyer, S., Azijn, H. Etravirine protects the activity of darunavir in the DUET trials. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P181.
80. Clumeck, N., Clotet, B., Johnson, M.A., De Smedt, G., Vingerhoets, J., Beets, G., Peeters, M. Virological response with fully active etravirine (ETR; TMC125) after forty eight weeks of treatment: Pooled results from the DUET-1 and DUET-2 trials. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P23.
81. Vingerhoets, J., Azijn, H., Tambuyzer, L. et al. Activity of etravirine on different HIV-I subtypes: Week 48 data of the pooled DUET trials and in vitro susceptibility in treatment-naïve patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P189.
82. Lalezari, J., Leider, J., De Smedt, G., Peeters, M., Sinha, R., Wilkin, T. Hepatic safety and tolerability of etravirine (ETR, TMC125) in HIV-1-infected treatment-experienced patients: Pooled analysis of the DUET-1 and DUET- 2 trials. Hepatology 2008, 48(4, Suppl.): Abst 347.
83. Madruga, J.V.R., Cassetti, I., Etzel, A., Enejosa, J., Zhou, Y., Cheng, A.K., Suleiman, J.M.A. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz in antiretroviral-naive patients through 7 years. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P4.
84. Maserati, R., Clerici, M., Lauriola, M. et al. Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P206.
85. Podsadecki, T.J., Rode, R.A., Marsh, T.M., Cohen, D.E., Naylor, C. Adherence with lopinavir/ritonavir (LPV/r) tablet and softgel (SGC) capsule based antiretroviral regimens and predictors of early treatment compliance. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P170.
86. Ayoub, A., Goodrich, J., Tressler, R., Mayer, H.B., Rajicic, N., Tomaszewski, K., Van Der Ryst, E. Incidence of infections in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) plus optimized background therapy (OBT). J Int AIDS Soc 2008, 11(Suppl. 1): Abst P154.
87. Bickel, M., Gute, P., Klauke, S., Mueller, A., Carlebach, A. Nevirapine (NVP), tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) is effective and well tolerated in naive HIV-1 infected patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P18.
88. Teppler, H., Rockstroh, J., Isaacs, R., Nguyen, B.Y., Hervey, C., Miller, M., Wan, H. Raltegravir clinical efficacy against B subtype and non-B subtype HIV-I is similar. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P207.
89. Molina, J.M., Cordes, C., Ive, P., Boven, K., Vanveggel, S., Williams, P., Vibhagool, A. Efficacy and safety of TMC278 in treatment-naive, HIVinfected patients: Week 96 data from TMC278-C204. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P2.
90. Graf, B., Taylor, K., Nelson, M., Gazzard, B.G., Gupta, A. Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naive individuals commencing therapy. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P16.
91. Wendig, A., Stephan, C., Khaykin, P. et al. Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P122.
92. Salami, O., Awunor, C., Ghaji, N. Sensory neuropathy not associated with interruption of ARV therapy in taking stavudine-lamivudine-nevirapine combination HAART in Abuja, Nigeria. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P149.
93. Rosso, R., Di Biagio, A., Parodi, A. et al. Impact on bone mineral density of tenofovir-containing HAART in HIV-I infected children and adolescents: A report from 5 years of clinical experience. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P215.
94. Van Lunzen, J., Fätkenheuer, G., Lutz, T. et al. Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice - two-year data from the German outpatient cohort. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P12.
95. Daniels, R.H., Gazzard, B.G., Nelson, M., Scourfield, A., Bower, M., Holmes, P. Comparing the efficacy of Truvada and Kivexa combination therapy in HAART-naive individuals with different viral loads. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P14.
96. Das, S., Arumainayagam, J., Ghanem, M., Chandramani, S., Riddell, L., Kumari, B. The TOKEN study: Safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naive predominantly black African HIV patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P15.
97. Bengleil, A.S., Kambraki, M., Martino, A.M., El Ammari, I., Idris Elteer, A., Al Fituri, O. Tenofovir toxicity in children: Two clinical cases. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P214.
98. Maggiolo, F., Airoldi, M., Trotta, M.P. et al. Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study). J Int AIDS Soc 2008, 11(Suppl. 1): Abst P167.
99. Macias, J., Orihuela, F., Rivero, A. et al. Hepatic safety of tipranavir/ritonavir (TPV/r)-based antiretroviral therapy: Effect of hepatitis virus co-infection and baseline liver fibrosis. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P141.
100. Ingiliz, P., Valantin, M.A., Thibault, V. et al. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine- resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008, 13(7): 895.
101. Nasta, P., Carosi, G., Matti, A., Gatti, F. Switching from zidovudine/ lamivudine (ZDV/LMV) to tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/LMV) in HIV/HCV co-infection (COTKI study). J Int AIDS Soc 2008, 11(Suppl. 1): Abst P267.
102. Ciraru-Vigneron, N., Mazeron, M.C., Lefevre, V., Barranger, E., Trout, H., Bergman, J.F., Chernai, N. Efficacy and safety of Truvada in HIV-I pregnant women: Report of 23 cases. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P222.
103. Frantzeskaki, F.G., Xanthaki, A., Betrosian, A. Efficacy of tigecycline versus high dose of ampicillin-sulbactam in ventilator associated pneumonia caused by acinetobacter baumannii. Intensive Care Med 2008, 34(Suppl. 1): Abst 0748.
104. Dartois, N., Castaing, N., Gandjini, H., Dukart, G., Cooper, A. Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience. Eur Respir J 2008, 32(Suppl. 52): Abst E1856.
105. Bechara, A., Romano, S., Casabé, A., Haime, S., Dedola, P., Hernández, C., Rey, H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008, 5(9):2170.
106. Langdahl, B., Ljunggren, Ö., Lems, W. et al. Women with severe osteoporosis treated with rhPTH(1-34) (teriparatide) improve quality of life regardless of incident fractures: 18 month results from the European Forsteo Observational Study (EFOS). J Bone Miner Res 2008, 23(Suppl. 1): Abst SU412.
107. Gacci, M., Del Popolo, G., Macchiarella, A., et al. Vardenafil improves bladder compliance in spinal cord injured patients: Results from a single dose, double-blind pilot study. J Urol 2008, 179(4, Suppl.): Abst 359.
108. Kyle, C., Zachariah, J., Kinch, H., Ellis, G., Andrews, C., Adekunle, F. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain. Int J Clin Pract 2008, 62(11): 1684.
109. Bezemer, G., Van Gool, A.R., Drenth, J.P. et al. A double blind, placebo-controlled trial with escitalopram to prevent psychiatric adverse events during treatment with pegylated interferon-alpha and ribavirin for chronic hepatitis C: The "Prevention Of Psychiatric Side effects (POPS)-study". Hepatology 2008, 48(4, Suppl.): Abst 1858.
110. Koytchev, R., Tzekova, V. Efficacy of epoetin zeta in patients with chemotherapy-induced anemia and hematological malignancies: Interim results. Haematologica 2008, 93(Suppl. 1): Abst 1132.
111. Okerson, T., Yan, P., Stonehouse, A., Brodows, R. et al. Exenatide improved systolic blood pressure compared to insulin or placebo in patients with type 2 diabetes. Diabetologia 2008, 51(Suppl. 1): Abst 877.
112. Moretto, T.J., Milton, D.R., Ridge, T.D., Macconell, L.A., Okerson, T., Wolka, A.M., Brodows, R.G. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30(8): 1448.
113. Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., Porter, L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 2008, 372: 1240.
114. Hanaire, H., Sreenan, S., Dornhorst, A. et al. Insulin-naive patients with type 2 diabetes and higher BMI experience weight loss when initiated onto insulin detemir: 12-week, 26-week and 52-week follow up data from PREDICTIVE. Diabetologia 2008, 51(Suppl. 1): Abst 976.
115. Pinget, M., Dornhorst, A., Gonbert, S. Insulin detemir use amongst older patients: Results from the 12-week, 26-week and 52-week cohorts of the PREDICTIVE study. Diabetologia 2008, 51(Suppl. 1): Abst 963.
116. Bays, H.E., Jones, P.H., Mohiuddin, S.M. et al. Long-term safety and efficacy of ABT-335 (fenofibric acid) in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Circulation 2008, 118(18, Suppl.): Abst 3732.
117. Yokote, K., Bujo, H., Hanaoka, H. et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201(2): 345.
118. Mazzone, T., Goldberg, R., Guyton, J., Weinstock, R., Polis, A., Tomassini, J., Tershakovec, A. Effect of ezetimibe/simvastatin (E/S) vs atorvastatin (A) on lipoprotein subclasses in type 2 diabetes (T2DM) patients with hypercholesterolemia (HC). J Clin Lipidol 2008, 2(Suppl. 5): Abst 46.
119. Bloomfield, D., Carlson, G.L., Sapre, A. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157(2): 352.
120. Devaraj, S., Rockwood, J., Jialal, I., Jialal, R. A pilot randomized placebo controlled trial of 2 aloe vera supplements in patients with prediabetes/ metabolic syndrome. Planta Med 2008, 74(9): Abst SL77.
121. Ikonomidis, I., Paraskevaidis, I., Lekakis, J. et al. Chronic inhibition of interleukin-1 activity by anakinra is more effective than corticosteroids in improving left ventricular function in patients with rheumatoid arthritis. Eur Heart J 2008, 29(Suppl.): Abst P1542.
122. Genovese, M.C., McKay, J.D., Nasonov, E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58(10): 2968.
123. Silverman, S.L., Christiansen, C., Genant, H.K. et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23(12): 1923.
124. Brown, J.P., Prince, R.L., Deal, C. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24(1): 153.
125. MacDonald, H.M., Boyd, S.K., Hanley, D.A. 12 Months of teriparatide therapy increases ultradistal radius bone strength in severely osteoporotic postmenopausal women. J Bone Miner Res 2008, 23(Suppl. 1): Abst SA504.
126. Merlotti, D., Rendina, D., Mossetti, G. et al. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget's disease of bone. J Bone Miner Res 2008, 23(Suppl. 1): Abst SA481.
127. Papadopoulos, K.P., Goel, S., Beeram, M. et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 2008, 14(21): 7110.
128. Sharma, S., Freeman, B., Turner, J., Symanowski, J., Manno, P., Berg, W., Vogelzang, N. A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors. Invest New Drugs 2009, 27(1): 63.
129. Tabernerol, J., Offski, P.S., Dirix, L. et al. First-in-human study of the first-in- class Hdm2 inhibitor. Eur J Cancer Suppl 2008, 6(12): Abst 1LB.
130. Overman, M.J., Kopetz, S., Varadhachary, G. et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 2008, 26(8): 794.
131. Pearson, M., Nix, J., Pruthi, R.S., Grigson, G., Wallen, E., Kim, W. A phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results. J Urol 2008, 179(4, Suppl.): Abst 331.
132. Kim, W.Y., Grigson, G.I., Wallen, E.M., Pruthi, R.S. A phase II study of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results. J Clin Oncol 2008, 26(15, Suppl.): Abst 11076.
133. Luu, T.H., Morgan, R.J., Leong, L. et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 2008, 14(21): 7138.
134. Fisher, G.A., Kuo, T., Ramsey, M. et al. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res 2008, 14(21): 7074.
135. Harrop, R., Shingler, W.H., Drury, N., Goonewardena, M., De Belin, J., Naylor, S., Treasure, P. Cross-trial analysis of immunological and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal and prostate cancer patients. Eur J Cancer Suppl 2008, 6(12): Abst 601.
136. Flaig, T.W., Kim, F.J., La Rosa, F.G., Breaker, K., Schoen, J., Russ, P.D. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 2009, 27(1): 83.
137. Sternberg, C.N., Labianca, R., Bracarda, S. et al. Safety and efficacy of sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of an Italian expanded-access program (EAP) with subpopulation analysis. J Urol 2008, 179(4, Suppl.): Abst 1217.
138. Tanguay, S., Wood, C., Bukowski, R. et al. A multicenter, randomized, phase III trial of a novel, autologous, therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma. Urology 2008, 72(Suppl. 5A): Abst POD-6.02.
139. Higginbotham, K.B., Lozano, R., Brown, T., Patt, Y.Z., Arima, T., Abbruzzese, J.L., Thomas, M.B. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2008, 134(12): 1325.
140. Piantedosi, F.V., Gilli, M., Caputo, F., Casale, B., Pontillo, A., Marsico, S.A., Bianco, A. Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC). Eur Respir J 2008, 32(Suppl. 52): Abst E4312.
141. Costa, D.B., Nguyen, K.S., Cho, B.C. et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008, 14(21): 7060.
142. Besse, B., Eaton, K.D., Soria, J.C. et al. Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Eur J Cancer Suppl 2008, 6(12): Abst 203.
143. Stroyakovskiy, D., Zhou, C., Guan, Z. et al. Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial. Eur Respir J 2008, 32(Suppl. 52): Abst 1549.
144. de Boer, R., Humblet, Y., Wolf, J. et al. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 2009, 20(3): 486.
145. Penel, N., Delcambre, C., Durando, X. et al. O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs 2008, 26(6): 561.
146. Tibes, R., Jimeno, A., Von Hoff, D.D. et al. Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125. J Clin Oncol 2008, 26(15, Suppl.): Abst 3531.
147. Iqbal, S., Lenz, H.J., Yang, D. et al. A randomized phase II study of BAY 43- 9006 in combination with gemcitabine in metastatic pancreatic carcinoma: A California Cancer Consortium study (CCC-P). J Clin Oncol 2008, 26(15, Suppl.): Abst 11082.
148. Morgan, M.A., Darcy, K.M., Rose, P.G. et al. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol 2008, 110(3): 329.
149. Nelson, J.B., Love, W., Chin, J.L. et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113(9): 2478.
150. Mathew, P., Pisters, L.L., Wood, C.G. et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2009, 181(1): 81.
151. Shah, S.K., Trump, D., Mohler, J.L., Sartor, O., Wilding, G.E. Phase II clinical trial of dutasteride in castration-recurrent prostate cancer. J Urol 2008, 179(4, Suppl.): Abst 515.
152. Klotz, L., Aprikian, A., Fleshner, N., Chin, J., Gleave, M., Zarenda, M. An open-label, phase II trial of 250 mg gefitinib (Iressa) in prostate cancer patients with early biochemical failure post-prostatectomy. Urology 2008, 72(Suppl. 5A): Abst POD-3.07.
153. Hussain, A., DiPaola, R.S., Baron, A.D., Higano, C.S., Tchekmedyian, N.S., Johri, A.R. Phase II trial of weekly patupilone in patients with castration- resistant prostate cancer. Ann Oncol 2009, 20(3): 492.
154. Maubec, E., Petrow, P., Duvillard, P. et al. Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin: Preliminary results of a phase II multicenter study. J Clin Oncol 2008, 26(15, Suppl.): Abst 9042.
155. Nachmany, I., Subhi, A., Meller, I., Gutman, M., Lahat, G., Merimsky, O., Klausner, J.M. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. Eur J Surg Oncol 2009, 35(2): 209.
156. Van Rhee, F., Fayad, L., Voorhees, P., et al. CNTO 328, a monoclonal antibody to interleukin-6, is active as a single agent in castleman's disease: Preliminary results of a phase I study. Blood 2008, 112(11): Abst 1008.
157. Kraj, M., Warzocha, K., Szpila, T., Poglod, R. The efficacy and safety of PAD regimen (bortezomib, doxorubicin, dexamethasone) in the treatment of plasma cell leukemia. Haematologica 2008, 93(Suppl. 1): Abst 0654.
158. Jinnai, I., Ohtake, S., Naoe, T. et al. Efficacy of allogeneic hematopoietic stem cell transplantation during first complete remission following imatinib-combined chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2008, 112(11): Abst 462.
159. Usuki, K., Naoe, T., Tojo, A. et al. A phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph-positive chronic myelogenous leukemia (CML) or relapsed/refractory Ph-positive acute lymphoblastic leukemia (ALL). Haematologica 2008, 93(Suppl. 1): Abst 1102.
160. Erba, H., Kantarjian, H., Claxton, D. et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Haematologica 2008, 93(Suppl. 1): Abst 0892.
161. Cashen, A.F., Schiller, G.J., O'Donnell, M.R., DiPersio, J.F., Baranwal, A., Cullen, M.T., Larsen, J.S. Preliminary results of a multicenter phase II trial of 5-day decitabine as front-line therapy for elderly patients with acute myeloid leukemia (AML). Blood 2008, 112(11): Abst 560.
162. Mufti, G., Rizzieri, D., Giles, F., Hudak, D., Karp, J., Vey, N. Treatment with VNP40101M (cloretazine) in patients with high risk myelodysplastic syndromes (MDS): Results of a subset population in a phase II study. Haematologica 2008, 93(Suppl. 1): Abst 0234.
163. Odenike, O.M., Alkan, S., Sher, D. et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008, 14(21): 7095.
164. Craddock, C., Russell, N., Buckley, L. et al. Patient and donor characteristics determine outcome after reduced intensity allogeneic stem cell transplantation in acute myeloid leukemia. Haematologica 2008, 93(Suppl. 1): Abst 0891.
165. Hu, J., Liu, Y.F., Wu, C.F et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009, 106(9): 3342.
166. Cortes, J., O'Brien, S., Borthakur, G. et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 2008, 112(11): Abst 182.
167. Baccarani, M., Rosti, G., Saglio, G. et al. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2008, 112(11): Abst 450.
168. Chu, S., Lin, A., Bhatia, R., Snyder, D.S., Forman, S.J., McDonald, T. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years. Blood 2008, 112(11): Abst 194.
169. O'Brien, S.G., Guilhot, F., Goldman, J.M. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008, 112(11): Abst 186.
170. Mayer, J., Klamova, H., Zackova, D. et al. Imatinib in the first-line CML treatment: An analysis of a comprehensive non-commercial database of all consecutive patients in a defined population. Haematologica 2008, 93(Suppl. 1): Abst 0554.
171. Deenik, W., Cornelissen, J.J., Verhoef, G.E.G. et al. Dose finding study of imatinib in combination with intravenous cytarabine: Feasibility and efficacy in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2008, 93(Suppl. 1): Abst 0884.
172. Guilhot, F., Preudhomme, C., Guilhot, J. et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): First results of the phase III (SPIRIT) trial from the French CML group (FI LMC). Blood 2008, 112(11): Abst 183.
173. Li, V., Liu, H.S.Y., Chan, F.H.Y. et al. Result of imatinib use in Chinese patients with chronic myeloid leukaemia in chronic phase. Haematologica 2008, 93(Suppl. 1): Abst 1291.
174. Baccarani, M., Rosti, G., Simonsson, B. et al. Cytogenetic and molecular response to imatinib in high risk (sokal) chronic myeloid leukemia (CML): Results of An European Leukemianet Prospective Study comparing 400 mg and 800 mg front-line. Blood 2008, 112(11): Abst 185.
175. Guilhot, F., Hughes, T.P., Cortes, J. et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS]). Blood 2008, 112(11): Abst 447.
176. Rosti, G., Baccarani, M., Poerio, A. et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: Results of a phase 2 trial of the GIMEMA CML Working Party. Blood 2008, 112(11): Abst 181.
177. Kantarjian, H.M., Giles, F.J., Bhalla, K.N. et al. Nilotinib in chronic myelogenous leukaemia in chronic phase (CML-CP) patients with imatinibresistance or intolerance: Updated phase 2 results. Haematologica 2008, 93(Suppl. 1): Abst 0883.
178. Cortes, J., O'Brien, S., Jones, D. et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 2008, 112(11): Abst 446.
179. Cortes, J., Wetzler, M., Akard, L. et al. Multicenter open label study of subcutaneous (SC) omacetaxine (QMA) in chronic myeloid leukemia (CML) patients (PTS) that are resistant or intolerant to two or more tyrosine kinase inhibitors (TKIS). Haematologica 2008, 93(Suppl. 1): Abst 0546.
180. Marin, D., Maloisel, F., Rousselot, P., Nicolini, F.E., Roy, L., Legros, L. Efficacy of subcutaneous homoharringtonine in chronic myeloid leukemia (CML) patients resistant to tyrosine kinase inhibitors (TKI) and harboring a BCR-ABL mutation. Haematologica 2008, 93(Suppl. 1): Abst 0139.
181. Gimeno, E., Alvarez, A., Pedro, C. et al. Reduced dose of non-pegylated liposomal doxorubicin with cyclophosphamide, vincristine and prednisone plus or minus rituximab for previously untreated elderly patients with aggressive lymphoma non suitables for standard chemotherapy. Haematologica 2008, 93(Suppl. 1): Abst 1302.
182. Di Bella, N., Asmar, L., Kolibaba, K.S. et al. Results of a phase II study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2008, 112(11): Abst 1572.
183. Grant, S., Sullivan, D., Roodman, D. et al. Phase I trial of bortezomib (NSC 681239) and flavopiridol (NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Blood 2008, 112(11): Abst 1573.
184. González-Barca, E., Canales, M., Salar, A. et al. Therapeutic compliance of 6 cycles of dose-dense immunochemotherapy, R-CHOP-14 plus pegfilgrastim in patients with diffuse large B-cell lymphoma (DLBCL): Preliminary results of a prospective Spanish trial. Haematologica 2008, 93(Suppl. 1): Abst 0768.
185. Tobinai, K., Ogura, M., Hatake, K. et al. Phase I and pharmacokinetic study of inotuzumab ozogamicin (CMC-544) as a single agent in Japanese patients with follicular lymphoma pretreated with rituximab. Blood 2008, 112(11): Abst 1565.
186. Goff, L., Summers, K., Iqbal, S. et al. Real-time quantitative PCR analysis for BCL2/IGH in the phase III first-line indolent trial of (90Y)-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma. Haematologica 2008, 93(Suppl. 1): Abst 0899.
187. Haioun, C., Jaeger, U., Lugtenburg, P et al. Risk of febrile neutropenia and use of G-CSF primary prophylaxis in non-Hodgkin's lymphoma patients receiving R-CHOP-21. Haematologica 2008, 93(Suppl. 1): Abst 0258.
188. Kirschbaum, M., Popplewell, L., Nademanee, A.P. et al. A phase 2 study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in relapsed or refractory indolent non-Hodgkin's lymphoma: A California Cancer Consortium study. Blood 2008, 112(11): Abst 1564.
189. Gómez Codina, J., Giraldo, P.G. Analysis of outcome and follow-up in non- Hodgkin's lymphoma patients treated with 90Y-ibritumomab tiuxetan for recurrent or refractory disease: Data obtained from radioimmunotherapy registry. Haematologica 2008, 93(Suppl. 1): Abst 0261.
190. Bartlett, N.L., Johnson, J.L., Wagner-Johnston, N., Ratain, M.J., Peterson, B.A. Phase II study of 9-aminocamptothecin in previously treated lymphomas: Results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol 2009, 63(5): 793.
191. Goy, A., Bernstein, S.H., Kahl, B.S. et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20(3): 520.
192. Zinzani, P.L., Buckstein, R., Haioun, C. et al. The efficacy and safety of lenalidomide oral monotherapy in patients with mantle cell lymphoma previously treated with bortezomib: Pooled data from two phase II studies (NHL-002 and NHL-003). Blood 2008, 112(11): Abst 1560.
193. Rolland, D., Ribrag, V., Haioun, C. et al. Farnesyltransferase inhibitor tipifarnib (Zarnestra) in refractory mantle cell lymphoma (MCL): A therapeutic target only for specific patients categorized by the 2-gene classifier for predictive response to tipifarnib. Blood 2008, 112(11): Abst 1561.
194. Cacchione, R., Bezares, F., Nucifora, E. et al. 90Y-ibritumomab tiuxetan treatment for relapsed and/or refractory B cell non-Hodgkin's lymphoma: Multi-institutional Argentinian study. Haematologica 2008, 93(Suppl. 1): Abst 0268.
195. Sortino, G.S., Milone, G.M., Leotta, G.L. et al. Use of KGF (palifermin) but not of G-CSF is associated to a reduced rate of infections after high dose chemotherapy and autologous PBSC transplantation. Haematologica 2008, 93(Suppl. 1): Abst 1507.
196. D'Amore, F., Valderrama, A., Gonzalez Diaz, M. et al. Analysis of quality of life (QOL) from the phase 3 randomized first-line indolent trial in patients with advanced follicular lymphoma receiving consolidation therapy with 90Y-ibritumomab tiuxetan. Haematologica 2008, 93(Suppl. 1): Abst 0802.
197. Bijou, F., Milpied, N., Dilhuydy, M. et al. Evaluation of pegfilgrastim efficacy in peripheral blood stem cell mobilization of patients with lymphoma. Haematologica 2008, 93(Suppl. 1): Abst 1082.
198. Hymes, K., Dummer, R., Sterry, W. et al. Phase I trial of oral vorinostat in combination with bexarotene in patients with advanced cutaneous T-cell lymphoma. J Clin Oncol 2008, 26(15, Suppl.): Abst 8613.
199. Sanz-Rodriguez, C., Geskin, L.J. Treatment of cutaneous T-cell lymphoma with vorinostat in combination with other agents: A case series. Haematologica 2008, 93(Suppl. 1): Abst 1305.
200. Ghobrial, I.M., Richardson, P., Padmanabhan, S. et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. Blood 2008, 112(11): Abst 832.
201. Kyrtsonis, M.C., Pangalis, G.A., Sachanas, S. et al. Prognostication of response to bortezomib, progression free and overall survival in relapsed/refractory myeloma patients. Haematologica 2008, 93(Suppl. 1): Abst 0653.
202. Saltarelli, F., Veggia, B., Moscetti, A. et al. Association of bortezomib and dexamethasone for the treatment of patients with relapsed multiple myeloma. Haematologica 2008, 93(Suppl. 1): Abst 1431.
203. Tsirigotis, P., Girkas, K.G., Giannopoulou, V. et al. Bortezomib plus dexamethasone in combination with melphalan or cyclophosphamide in the treatment of patients with relapsed or refractory multiple myeloma. Haematologica 2008, 93(Suppl. 1): Abst 1109.
204. Garcia Sanchez, R., Saldaña, R., Caparrós, I. et al. Efficacy and safety of bortezomib plus dexamethasone in relapsed/refractory multiple myeloma. Haematologica 2008, 93(Suppl. 1): Abst 1295.
205. Gozzetti, A., Marchini, E., Lauria, F., Bocchia, M., Defina, M., Fabbri, A. Bortezomib, pegylated liposomal doxorubicin and dexamethasone (BPEGHLD- D) as therapy for patients with relapsed refractory multiple myeloma. Haematologica 2008, 93(Suppl. 1): Abst 1111.
206. Ailawadhi, S., Miller, K.C., Depaolo, D. et al. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT) for the treatment of previously untreated multiple myeloma. Haematologica 2008, 93(Suppl. 1): Abst 0208.
207. Terpos, E., Baltathakis, I., Anargyrou, K. et al. PAD (bortezomib/adriamycin/ dexamethasone) regimen is very effective in high risk, newly-diagnosed myeloma, reduces dickkopf-1 and abnormal bone resorption and normalizes impaired angiopoietin-1/-2 ratio. Haematologica 2008, 93(Suppl. 1): Abst 0656.
208. Tosi, P., Zamagni, E., Tacchetti, P et al. Bortezomib-thalidomide- dexamethasone as primary induction therapy for newly diagnosed multiple myeloma significantly decreases bone resorption while sparing bone formation as compared to thalidomide-dexamethasone. Haematologica 2008, 93(Suppl. 1): Abst 0659.
209. Mazzone, C., Gentile, M., Vigna, E. et al. Bortezomib-based regimens as induction and maintenance treatment in multiple myeloma (MM) patients not eligible for aggressive therapy. Haematologica 2008, 93(Suppl. 1): Abst 1434.
210. Pisani, F., Cordone, I., Dessanti, M.L. et al. Bortezomib, liposomal doxorubicin and dexamethasone regimen for relapsed or refractory multiple myeloma and introduction of serum free light chains (SFLC) in response monitoring: Preliminary data. Haematologica 2008, 93(Suppl. 1): Abst 1106.
211. Palumbo, A., San-Miguel, J., Khuageva, N. et al. Prolonged therapy with bortezomib plus melphalan-prednisone (VMP) results in improved quality and duration of response in the phase III VISTA study in previously untreated multiple myeloma (MM). Haematologica 2008, 93(Suppl. 1): Abst 0207.
212. Jagannath, S., Vij, R., Stewart, A.K. et al. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood 2008, 112(11): Abst 864.
213. Mikala, G. Safe and effective mobilization of stem cells in multiple myeloma following priming by high-dose cyclophosphamide and bortezomib. Haematologica 2008, 93(Suppl. 1): Abst 0655.
214. Kurzrock, R., Fayad, L., Voorhees, P. et al. A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non- Hodgkin's lymphoma, multiple myeloma, or castleman's disease. Blood 2008, 112(11): Abst 1009.
215. Roussel, M., Huynh, A., Moreau, P. et al. Bortezomib (BOR) and high dose melphalan (HDM) as conditioning regimen before autologous stem cell transplantation (ASCT) for de novo multiple myeloma (MM): Final results of the IFM phase II study VEL/MEL. Blood 2008, 112(11): Abst 160.
216. Sekeres, M.A., List, A.F., Cuthbertson, D. et al. Final results from a phase I combination study of lenalidomide and azacitidine in patients with higher- risk myelodysplastic syndromes (MDS). Blood 2008, 112(11): Abst 221.
217. Faderl, S., Garcia-Manero, M., Ravandi, F. et al. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). Blood 2008, 112(11): Abst 222.
218. Moller, I., Kündgen, A., Blum, S., Germing, U., Haas, R., Habersang, K., Gattermann, N. Complete response of a patient with RAEB-II to sequential therapy with tipifarnib, 5-azacytidine and decitabine: A case report. Haematologica 2008, 93(Suppl. 1): Abst 1145.
219. Mesa, R.A., Verstovsek, S., Kantarjian, H.M. et al. INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and Frank cachexia in patients with myelofibrosis (MF). Blood 2008, 112(11): Abst 1760.
220. Verstovsek, S., Kantarjian, H.M., Pardanani, A.D. et al. The JAK inhibitor, INCB018424 demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ET-MF). Blood 2008, 112(11): Abst 1762.
221. Palumbo, A., Boccadoro, M., Gay, F. et al. Bortezomib-doxorubicin- dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood 2008, 112(11): Abst 159.
222. Pereira, H., Lopes-Lima, J., Gil-Nagel, A., Cramer, J., Maia, J., Almeida, L., Soares-da-Silva, P. Improvement in quality-of life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA- 2093-303 study. Epilepsia 2008, 49(Suppl. 7): Abst 3.240.
223. Soares-da-Silva, P., Martins-da-Silva, A., Gabbai, A.A., Ben-Menachem, E., Cramer, J., Maia, J., Almeida, L. Improvement in quality-of life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-302 study. Epilepsia 2008, 49 (Suppl. 7):Abst 3.254.
224. Rosenfeld, W., Fountain, N.B., Rosenow, F., Gil-Nagel, A., Sullivan, T., Hebert, D., Doty, P. Safety and tolerability of lacosamide: A summary of adverse events in epilepsy clinical trials. Epilepsia 2008, 49(Suppl. 7): Abst 3.245.
225. Rosenfeld, W., Rudd, D., Hebert, D., Doty, P. Lacosamide efficacy is independent of concomitant AED(S) treatment. Epilepsia 2008, 49(Suppl. 7): Abst 3.246.
226. Elger, C., French, J., Halász, P. et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures: Pooled analysis of three double-blind phase III clinical studies. Epilepsia 2008, 49(Suppl. 7): Abst 3.199.
227. Ben-Menachem, E., Gabbait, A.A., Hufnagel, A., Maia, J., Almeida, L., Soares-da-Silva, P. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA- 2093-302 study. Epilepsia 2008, 49(Suppl. 7): Abst 3.192.
228. Gil-Nagel, A., Lopes-Lima, J., Maia, J., Almeida, L., Soares-da-Silva, P. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study. Epilepsia 2008, 49(Suppl. 7): Abst 3.210.
229. Cramer, J., Elger, C., Halász, P. et al. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-301 study. Epilepsia 2008, 49(Suppl. 7): Abst 3.197.
230. Gabbai, A.A., Ben-Menachem, E., Maia, J., Almeida, L., Soares-da-Silva, P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension of study BIA-2093-302. Epilepsia 2008, 49(Suppl. 7): Abst 3.208.
231. Lopes-Lima, J., Gil-Nagel, A., Maia, J., Almeida, L., Soares-da-Silva, P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension of study BIA-2093-303. Epilepsia 2008, 49(Suppl. 7): Abst 3.227.
232. Halász, P., Elger, C., Guekht, A., Maia, J., Almeida, L., Soares-da-Silva, P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-301. Epilepsia 2008, 49(Suppl. 7): Abst 3.213.
233. French, J.A., Mansbach, H. 1200 mg/day retigabine as adjunctive therapy in adults with refractory partial-onset seizures. Epilepsia 2008, 49(Suppl. 7): Abst 1.256.
234. Goodman, A.D., Rossman, H., Bar-Or, A. et al. GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009, 72(9): 806.
235. Havrdova, E., Galetta, S., Hutchinson, M. et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing- Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009, 8(3): 254.
236. Kushida, C.A., Becker, P.M., Ellenbogen, A.L., Canafax, D.M., Barrett, R.W. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009, 72(5): 439.
237. Pollack, M.H., Endicott, J., Liebowitz, M. et al. Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment. J Psychiatr Res 2008, 42(12): 1042.
238. Findling, R.L., Short, E.J., Leskovec, T., Townsend, L.D., Demeter, C.A., McNamara, N.K., Stansbrey, R.J. Aripiprazole in children with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2008, 18(4): 347.
239. Dunn, R.T., Stan, V.A., Chriki, L.S., Filkowski, M.M., Ghaemi, S.N. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. J Affect Disord 2008, 110(1-2): 70.
240. Vieta, E., T'joen, C., McQuade, R.D. et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: A placebo-controlled study. Am J Psychiatry 2008, 165(10): 1316.
241. Savaskan, E., Müller, S.E., Böhringer, A., Schulz, A., Schächinger, H. Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. Int J Neuropsychopharmacol 2008, 11(3): 381.
242. Kaufman, J.M., Rosen, R.C., Mudumbi, R.V., Tesfaye, F., Hashmonay, R., Rivas, D. Treatment benefit of dapoxetine for premature ejaculation: Results from a placebo-controlled phase III trial. BJU Int 2009, 103(5): 651.
243. Meisenzahl, E.M., Schmitt, G., Gründer, G. et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: An iodine- 123-iodobenzamide SPET study. Pharmacopsychiatry 2008, 41(5): 169.
244. Boulton, D.W., Kollia, G., Mallikaarjun, S., Komoroski, B., Sharma, A., Kovalick, L.J., Reeves, R.A. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokin 2008, 47(7): 475.
245. Lettieri, C., Quast, T., Eliasson, A., Greenburg, D. Eszopiclone improves the quality of polysomnography: Prospective, blinded, placebo-controlled trial. Eur Respir J 2008, 32(Suppl. 52): Abst P808.
246. Canaud, B., Mingardi, G., Braun, J. et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008, 23(11): 3654.
247. Roehrborn, C.G., McVary, K.T., Elion-Mboussa, A., Viktrup, L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008, 180(4): 1228.
248. Krishna, R., Wong, P., Stevens, C. et al. Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model. J Clin Pharmacol 2008, 48(10): 1237.
249. Porst, H., Rajfer, J., Casabé, A. et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008, 5(9): 2160.
250. Becher, E., Aires, B., Roehrborn, C., Montorsi, F., Major-Walker, K., Wilson, T.H., Siami, P. Improvements in storage and voiding symptoms with dutasteride, tamsulosin and the combination: Post-hoc analysis of the 2-year data from the CombAT trial. J Urol 2008, 179(4, Suppl.): Abst 2030.
251. Bhowmick, B., Singh, D., Molfino, N. et al. A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma. Eur Respir J 2008, 32(Suppl. 52): Abst 3021.
252. LaForce, C., Korenblat, P., Osborne, P., Dong, F., Owen, R., Higgins, M. 24-Hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol. Eur Respir J 2008, 32(Suppl. 52): Abst 3023.
253. Kulus, M., Bridges, T., Fowler-Taylor, A., Blogg, M., Jimenez, P. A randomized controlled study of omalizumab in children with moderate-tosevere persistent allergic asthma. Eur Respir J 2008, 32(Suppl. 52): Abst E3064.
254. Nair, P., Pizzichini, M.M., Kjarsgaard, M. et al. Mepolizumab for prednisone- dependent asthma with sputum eosinophilia. New Engl J Med 2009, 360(10): 985.
255. Haldar, P., Brightling, C.E., Hargadon, B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New Engl J Med 2009, 360(10): 973.
256. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med 2008, 359(15): 1543.
257. Jemec, G.B., Ganslandt, C., Ortonne, J.P. et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, doubleblind, controlled trial. J Am Acad Dermatol 2008, 59(3): 455.
258. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008, 23(11): 2484.
259. Bucci, F.A. Jr., Waterbury, L.D. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg 2008, 34(9): 1509.
260. Lane, S.S., Osher, R.H., Masket, S., Belani, S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 2008, 34(9): 1451.
261. Turpie, A.G.G., Lassen, M.R., Kakkar, A.K. e al. A meta-analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: Effect on symptomatic venous thromboembolism, all-cause mortality and bleeding. Eur Heart J 2008, 29(Suppl.): Abst P4760.
262. Brancato, T., Orsolini, G., D'Ascenzo, R., Nupieri, P., Paulis, G., Alvaro, R. Sexual rehabilitation after radical retropubic prostatectomy (RRP): Results of a clinical study on 40 patients treated with tadalafil and alprostadil. Urology 2008, 72(Suppl. 5A): Abst UP.66.
263. Doering, M., Handgretinger, R., Lang, P., Müller, I. Safety and feasibility of posaconazole as oral antifungal prophylaxis following allogeneic hematopoietic stem cell transplantation in 10 pediatric patients under 12 years of age. Haematologica 2008, 93(Suppl. 1): Abst 0822.
264. Khosravan, R., Kukulka, M.J., Wu, J.T. et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008, 48(9): 1014.
265. Sandström, E., Nilsson, C., Hejdeman, B. et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198(10): 1482.
266. Kuo, P., Gentilcore, D., Nair, N. et al. Effects of the nitric oxide (NO) synthase inhibitor, ng-nitro-l-arginine-methyl-ester (L-NAME), on delayed gastric emptying induced by hyperglycaemia in healthy humans. J Gastroenterol Hepatol 2008, 23(Suppl. 4): Abst.
267. Salinsky, M.C., Munoz, S., Storzbach, D. Pregabalin effects on the EEG and cognition: A randomized, double-blind study in healthy volunteers. Epilepsia 2008, 49(Suppl. 7): Abst 1.319.
268. Coltamai, L., Bucher, M., Maillard, M.P. et al. Vascular effects of RWJ- 676070, a selective combined V1a/V2 vasopressin receptor antagonist. Clin Pharmacol Ther 2009, 85(2): 145.
269. Burnett-Bowie, S.M., Henao, M.P., Leder, B.Z., Lee, H., Dere, M.E. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D and FGF-23 levels in healthy men. J Bone Miner Res 2008, 23(Suppl. 1): Abst SU169.